I undersøgelsen var den kumulative del af patienter, som udviklede progression af invaliditeten (målt med “ Kaplan- Meier life table ” analyse) ved slutningen af de to år 35% for patienter i placebo- gruppen og 22% for patienter i AVONEX- gruppen.
In the study, the cumulative percentage of patients who developed disability progression (by Kaplan-Meier life table analysis) by the end of two years was 35% for placebo-treated patients and 22% for AVONEX-treated patients.